This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

       

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Unit for Hours:H

Unit for Minutes: M

Loading text: $loading

Filter redirection page URL: /en-ie/events/

Login overlay needed?:

Filter Tags:All Medical indications|All Products|All Therapy Area

Filter Tags values when filtered by all Tags:All Medical indications|All Products|All Therapy Area

OutofBox filter category name:Format

Filter Reset all button text:Reset All

Filter Apply button text:Apply

Events registration success message: Registration successful

Events registration failure message: Registration failure

Events un-registration success message: Un-Registration successful

Events un-registration failure message: Un-Registration failure

Reset all default value: false

Show More Naivagation Values: 10|25|50

Previous Text label: Previous

Next Text label: Next

Show Text label: Show:

Seats left Text: spaces left

No Seats left Text: No spaces left

Text Area Blank copy in Email Template:Not provided

 

*For further details please see the Tivicay and Epivir (lamivudine) SPCs accessible using the links below.
 

Tivicay▼ (dolutegravir) Prescribing Information

Epivir (lamivudine) Prescribing Information

 

Webinar

Webinar Series

Access interactive product and scientific seminars regularly held by GSK experts from the comfort of your own office on any device you chose. IE/COM/0016/18

See full schedule

Nucala

NUCALA is a targeted anti-interleukin-5 add-on therapy for your adult patients with severe refractory eosinophilic asthma.  Here you can access the latest news, clinical data and resources for Nucala.

Learn More

Prescribing Information

Trelegy Ellipta

The only COPD triple therapy delivered in a single daily inhalation. Trelegy Ellipta once-daily (OD) is indicated for maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS & a LABA.

Learn More

Prescribing Information

JULUCA ▼

(dolutegravir/rilpivirine)

JULUCA is indicated for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable ARV regimen for  ≥ 6 months with no history of virological failure and no known or suspected resistance to any NNRTI or INI.

Explore JULUCA

Prescribing Information

Vaccines

Bexsero is indicated for the active immunisation of individuals from 2 months of age and older against invasive meningococcal disease (IMD) caused by Neisseria meningitidis group B. Here you can access information on IMD, disease burden and the meningococcal group B vaccine.

Learn More

Prescribing Information

GSK Registration

Stay Informed

Sign up to receive email alerts from GSK including important supply updates, new product information and events we are running.

Register Now

  

Chat Icon

Click-To-Chat


Connect with a member from the GSK Medical Information team using our LiveChat Service.

Click here

 

Vaccines Stock Update

Find out information on the current stock levels of our vaccines.

Vaccines Stock Update

View our products

View our products

Find comprehensive information on our products including resources for patients.

Expert perspectives

Respiratory Knowledge Base

Watch videos on everything from disease and patient management to research and development. 

Find out more

TRELEGY Ellipta was developed in collaboration with INNOVIVA Inc.

INVA_ID_PMS_122115

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the GSK group of companies.